William Johnson, MD
Pulmonary Disease · Lincoln, NENPI 1932178548
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,170 of the $17,729 with a category attached, or 74.3%. United Therapeutics Corporation accounts for 83.4% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $13,829 and has fallen 87.9% since, to $1,667 in 2025. Among pulmonary disease clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 128 payments — averaging $138.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$15K
- Inspire Medical Systems, Inc.$1K
- Sunovion Pharmaceuticals Inc.$242
- GSK$159
- AstraZeneca$155
- Harmony Biosciences LLC$129
- plus $1K from 26 others
Across 4 payments — averaging $3175.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$12K
- Actelion Pharmaceuticals, Ltd$700
What the payments were for
- Speaking & faculty fees$13,17074%
- Travel & lodging$2,01811%
- Food & beverage$2,35713%
- Education$1841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 19 | $14,787 |
| Inspire Medical Systems, Inc. | 12 | $1,172 |
| Sunovion Pharmaceuticals Inc. | 16 | $242 |
| GSK | 17 | $159 |
| AstraZeneca(2 entities) | 4 | $155 |
| Harmony Biosciences LLC | 3 | $129 |
| Actelion Pharmaceuticals US, Inc. | 4 | $120 |
| Genentech USA, Inc. | 5 | $92 |
| Amgen | 5 | $90 |
| Sanofi | 5 | $82 |
| Boehringer Ingelheim | 5 | $76 |
| Grifols USA, LLC | 3 | $71 |
| Baxter Healthcare | 3 | $61 |
| Resmed Corp | 1 | $48 |
| Verona Pharma, Inc. | 2 | $42 |
| Regeneron Healthcare Solutions, Inc. | 3 | $42 |
| Abiomed | 1 | $38 |
| Tactile Systems Technology Inc | 1 | $35 |
| Insmed, Inc. | 2 | $34 |
| 3b Medical, Inc. | 2 | $30 |
| Jazz Pharmaceuticals Inc. | 2 | $30 |
| AbbVie | 2 | $29 |
| Novartis | 2 | $27 |
| Merck | 1 | $22 |
| Astellas Pharma US Inc | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
| Electromed, Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $13 |
| Circassia Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,729 in reported general payments places this provider in the 90th percentile of 81 pulmonary disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 108 | $1,315,214 |
| UptraviSelexipag | 34 | $811,938 |
| OfevNintedanib Esylate | 43 | $557,709 |
| Orenitram ErTreprostinil Diolamine | 36 | $247,361 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 152 | $103,638 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 97 | $78,345 |
| Ambrisentan | 18 | $66,435 |
| TezspireTezepelumab-Ekko | 12 | $55,400 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 60 | $38,128 |
| Tadalafil | 19 | $36,409 |
| Breo ElliptaFluticasone/Vilanterol | 67 | $34,499 |
| Spiriva RespimatTiotropium Bromide | 54 | $33,808 |
| SymbicortBudesonide/Formoterol Fumarate | 108 | $28,782 |
| XareltoRivaroxaban | 20 | $15,206 |
| DuleraMometasone/Formoterol | 39 | $14,685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $120 | $2,127,153142 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $76 | $629,644157 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $155 | $162,527217 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $159 | $162,424281 claims |
| Johnson & JohnsonXarelto | $14 | $15,20620 claims |
| MerckDulera | $22 | $14,68539 claims |
| PfizerEliquis | $14 | $7,67813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 81 pulmonary disease providers in Nebraska.
Other pulmonary disease in Lincoln
- Ryan MartinLincoln$600K
- Douglas FiedlerLincoln$23K
- Kevin ReichmuthLincoln$22K
- Harvey HopkinsLincoln$18K
- Matthew MaslonkaLincoln$14K
- Jakeb RiggleLincoln$13K
- Jonathan SpencerLincoln$9K
- Louis VioliLincoln$6K
- Jeffrey JarrettLincoln$5K
- Sean BarryLincoln$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.